Polysaccharide nanosystems for future progress in cardiovascular pathologies.
Natural polysaccharides have received a lot of attention in the biomedical field. Indeed, sources of polysaccharides, extracted or produced from plants, bacteria, fungi or algae, are diverse and renewable. Moreover, recent progresses in polysaccharide chemistry and nanotechnologies allow elaborating new dedicated nanosystems. Polysaccharide-based nanosystems may be designed for interacting in several biological processes. In particular, the atherothrombotic pathology is highly concerned by polysaccharide-mediated recognition. Atherothrombotic diseases, regardless of the anatomical localization, remain the main causes of morbidity and mortality in the industrialized world. This review intends to provide an overview on polysaccharide-based nanosystems as drug delivery systems and targeted contrast agents for molecular imaging with an emphasis on the treatment and imaging of cardiovascular pathologies.
Inserm, U698, Cardiovascular Bio-Engineering; X. Bichat hospital, 46 rue H. Huchard, F-75018, Paris, France; Université Paris 13, Sorbonne Paris Cité, F-93430, Villetaneuse, France.
Amanda Karine Andriola
AK
Silva
Inserm, U698, Cardiovascular Bio-Engineering; X. Bichat hospital, 46 rue H. Huchard, F-75018, Paris, France; Université Paris 13, Sorbonne Paris Cité, F-93430, Villetaneuse, France.
Didier
D
Letourneur
Inserm, U698, Cardiovascular Bio-Engineering; X. Bichat hospital, 46 rue H. Huchard, F-75018, Paris, France; Université Paris 13, Sorbonne Paris Cité, F-93430, Villetaneuse, France.
Cédric
C
Chauvierre
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry* / Q000627:therapeutic use; D011134:Polysaccharides / Q000737:chemistry* / Q000627:therapeutic use
D011134:Polysaccharides
Atherothrombosis; Drug delivery; Molecular imaging.; Nanosystems; Polysaccharides